Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Censoring Survival Data

Censoring Survival Data

Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Assumptions of Survival Analysis

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Introduction To Survival Analysis

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial.

JAMA network open·2026

Same author

Exploring Inflation-Related Public Discourse Relevant to Social Determinants of Health Using Social Media Data.

International journal of environmental research and public health·2026

Same author

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

iScience·2026

Same author

Bayesian Sparse Regression for Microbiome-Metabolite Data Integration.

Statistics in medicine·2026

Same author

Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis.

The oncologist·2026

Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026

Search research articles

Related Experiment Video

Updated: May 26, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

Meta-analysis of Censored Adverse Events.

Xinyue Qi¹, Shouhao Zhou², Christine B Peterson¹

¹Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

The New England Journal of Statistics in Data Science

|February 24, 2025

Summary

This summary is machine-generated.

This study introduces a Bayesian method to accurately estimate drug safety by including censored adverse event (AE) data in meta-analyses. The approach improves incidence rate estimations, crucial for reliable drug safety assessments.

Keywords:

Adverse drug reaction Bayesian inference Drug safety Incomplete reporting MAGEC Meta-analysis

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: May 26, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

Pharmacovigilance
Biostatistics
Drug Safety

Background:

Meta-analysis is vital for drug safety assessment due to underpowered clinical trials for adverse event (AE) detection.
Incomplete AE reporting, especially for rare events below study thresholds, leads to biased incidence rate estimations in meta-analyses.
Existing statistical methods inadequately address censored AE data in drug safety meta-analyses.

Purpose of the Study:

To develop and validate a Bayesian approach for meta-analysis of drug safety data that accounts for censored and rare adverse events.
To improve the accuracy of incidence probability estimation in drug safety meta-analyses.

Main Methods:

A novel Bayesian statistical framework was developed to incorporate censored adverse event data.
Simulation studies were conducted to evaluate the performance of the proposed method against existing approaches.
The method was applied to meta-analysis of drug safety data, focusing on incidence rate estimation.

Main Results:

The proposed Bayesian method demonstrated improved accuracy in point and interval estimation of AE incidence probabilities.
The method effectively accommodates censored AE data, reducing bias in meta-analysis results.
Simulation studies confirmed the enhanced performance, particularly when dealing with rare or censored safety signals.

Conclusions:

The developed Bayesian approach offers a robust solution for handling censored and rare adverse events in drug safety meta-analyses.
This method can lead to more accurate and reliable assessments of drug safety profiles.
Implementation of this approach can support better-informed decision-making in pharmaceutical safety evaluations.